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Flaviviruses are a group of small RNA viruses that cause severe disease in humans worldwide and are the
target of several vaccine development programs. A primary goal of these efforts is to elicit a protective
humoral response directed against the envelope proteins arrayed on the surface of the flavivirus virion.
Advances in the structural biology of these viruses has catalyzed rapid progress toward understanding
the complexity of the flavivirus immunogen and the molecular basis of antibody-mediated neutralization.
These insights have identified factors that govern the potency of neutralizing antibodies and will inform
the design and evaluation of novel vaccines.Flaviviruses are a group of 70 positive strand RNA viruses,
many of which are transmitted through the bite of an infected
mosquito or tick and cause a variety of severe diseases in
humans (Lindenbach et al., 2007). Dengue virus (DENV) is amos-
quito-borne flavivirus endemic to tropical and subtropical re-
gions of the world, with 30% of the human population at risk
of infection. Four antigenically related serotypes of DENV circu-
late in nature and are responsible for more than 50million human
infections each year (Kyle and Harris, 2008). While themajority of
these infections are inapparent, clinical manifestations range
from a self-limited febrile illness to a potentially fatal disease
characterized by hemorrhage (dengue hemorrhagic fever; DHF)
and/or shock (dengue shock syndrome; DSS) (Gubler, 1998).
The incidence of DHF/DSS has increased significantly during
the past 50 years and is due, in part, to the global spread of mul-
tiple DENV serotypes (Kyle and Harris, 2008). Other members of
this genus with amajor impact on public health include yellow fe-
ver virus (YFV), Japanese encephalitis virus (JEV), tick-borne en-
cephalitis virus (TBEV), and West Nile encephalitis virus (WNV).
In light of the global clinical and economic burden of dengue in-
fection, thedevelopment of a vaccine is being actively pursuedby
both the private and public sector (reviewed by Whitehead et al.,
2007). Based onpast achievementswith other flaviviruses and re-
cent scientific advances in understanding dengue biology, there
is cause foroptimismthat theseeffortswill yielda vaccinecapable
of protecting against DENV infection. Safe and effective vaccines
that prevent infection by other flaviviruses have been developed
including the live-attenuated 17D vaccine for YFV (Monath,
2005), an inactivated TBEV vaccine (Heinz and Kunz, 2004), and
both live-attenuated and inactivated JEV vaccines (Hennessy
et al., 1996; Kurane and Takasaki, 2000; Xin et al., 1988). Alto-
gether, these have been administered to more than 400 million
individuals, with relatively few (albeit in some cases serious) ad-verse events (Monath, 2007). These successful vaccine efforts
have established the immunogenicity of flaviviruses in humans,
facilitated an understanding of surrogate markers of protection,
and identified strategies and vectors capable of eliciting protec-
tive responses. Finally, as the immune responseelicitedbynatural
DENV infection confers life-long protection against reinfection by
viruses of the same serotype, vaccination and immunologic pro-
tection against DENV should be feasible (Whitehead et al., 2007).
The development of a DENV vaccine, however, is complicated
by a requirement to protect simultaneously against the four sero-
types of DENV and the potential for a suboptimal vaccine-
induced immune response to exacerbate disease. Prospective
clinical studies suggest that the risk of severe disease is signifi-
cantly greater for individuals experiencing DENV infection for the
second time with a heterologous DENV serotype (Vaughn et al.,
2000). The viral and host factors that contribute to the develop-
ment of severe DENV disease following secondary infection
remain controversial and are an area of intensive study (Green
and Rothman, 2006; Halstead, 2003). A central role for DENV-re-
active antibody in initiating the pathogenesis of severe disease is
strongly suggested by the finding that infants of DENV-immune
mothers are at increased risk for DHF/DSS following primary in-
fection during their first year of life (Chau et al., 2008; Kliks et al.,
1988). In this context, passively transferred maternal antibody
increases the severity of disease, presumably by promoting
more efficient infection of Fc-g-receptor-expressing myeloid
cells in vivo: this phenomenon is called antibody-dependent
enhancement of infection; ADE) (Halstead and O’Rourke, 1977).
The potential for vaccine-induced antibody responses to
protect against infection or exacerbate disease highlights the
need to understand, in structural and biochemical detail, the
complexity of the humoral immune response against flaviviruses,
including DENV. Over the past few years, rapid progress hasCell Host & Microbe 4, September 11, 2008 ª2008 Elsevier Inc. 229
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anti-flavivirus antibodies. These efforts have been catalyzed in
part by support from the Research and Development Network
of the Pediatric Dengue Vaccine Initiative (PDVI; http://www.
pdvi.org), a Bill andMelinda Gates Foundation-sponsored global
network of basic science and clinical investigators. This Review
will discuss themolecular basis of antibody-mediated neutraliza-
tion and enhancement of flavivirus infection and how these
concepts inform the rational design and evaluation of vaccines,
therapeutics, and diagnostics.
The Critical Role of Antibodies in Protection against
Flavivirus Infection
Humoral immunity is a component of the host response to flavi-
viruses that is essential to control dissemination of infection, and
for encephalitic flaviviruses, to arrest viral replication in the cen-
tral nervous system. Passive transfer of polyclonal or monoclo-
nal antibodies (mAbs) against flavivirus proteins protects mice
against lethal challenge in several different flavivirus systems
(reviewed in Pierson and Diamond, 2008 and Roehrig et al.,
2001). Furthermore, mice that lack B cells are more vulnerable
to flavivirus infection (Chambers et al., 2008; Diamond et al.,
2003; Halevy et al., 1994). Antibodies are believed to protect
against flavivirus infection through multiple mechanisms, includ-
ing (1) direct neutralization of receptor binding, (2) inhibition of
viral fusion, (3) Fc-g-receptor-dependent viral clearance, (4)
complement-mediated lysis of virus or infected cells, and (5)
antibody-dependent cytotoxicity of infected cells.
Flavivirus Structure
Flaviviruses are relatively small (50 nm diameter) spherical
virions that encapsidate a nonsegmented RNA genome of
positive-sense polarity (Lindenbach et al., 2007). This 11 kb vi-
ral RNA encodes a single polyprotein, which is cleaved by viral
and cellular proteases into ten functionally distinct proteins
(three structural and seven nonstructural proteins). Virions are
composed of the capsid (C), premembrane/membrane (prM/M)
and envelope structural proteins (E), the viral RNA, and a lipid en-
velope derived from the endoplasmic reticulum (ER).
The structure of the ectodomain of the E protein of several
flaviviruses has been resolved by X-ray crystallography and is
composed of three distinct domains connected to the viral mem-
brane by a helical stem anchor and two antiparallel transmem-
brane domains (reviewed inMukhopadhyay et al., 2005). Domain
III (E-DIII) adopts an immunoglobulin-like fold and has been sug-
gested to play a critical role in receptor interactions. Domain II
(E-DII) is composed of two long finger-like structures and con-
tains a highly conserved 13 amino acid fusion loop (E-DII-FL).
The central domain of E (domain I; E-DI) is a nine-stranded b-bar-
rel that is connected to E-DIII and E-DII by one and four flexible
linkers, respectively (Figure 1A). E proteins are important for viral
assembly, receptor attachment, entry, viral fusion, and possibly
immune evasion during the flavivirus life cycle and, thus, are dy-
namic proteins required to adopt several distinct conformations
and arrangements on the virus particle (Arjona et al., 2007; Mu-
khopadhyay et al., 2005). Moreover, the primary target for neu-
tralizing anti-flavivirus antibodies is the E protein (Roehrig, 2003).
Flaviviruses assemble at the endoplasmic reticulum (ER) and
bud into the lumen as immature virus particles in which three230 Cell Host & Microbe 4, September 11, 2008 ª2008 Elsevier Inc.pairs of E and prM interact as trimers arranged as sixty spiked
projections with icosahedral symmetry (Figure 1B) (Zhang
et al., 2003, 2007). The E proteins of each trimer project away
from the surface of the virion and interact with prM via the distal
end of E-DII including the fusion loop (Li et al., 2008). PrM on im-
mature virions restricts the ability of E proteins to undergo oligo-
meric rearrangement in the low pHGolgi-derived secretory com-
partments during viral egress, thus preventing premature and
adventitious fusion (Guirakhoo et al., 1991; Heinz et al., 1994).
As immature virions traffic through the acidic compartments of
the trans-Golgi network (TGN), changes in the orientation of
prM and E proteins unmask a site for the cellular serine protease
furin (Stadler et al., 1997; Yu et al., 2008). In this low pH environ-
ment, the E proteins of immature virions form antiparallel dimers
that lie flat against the surface of the virion and are arranged with
T = 3 quasi-icosahedral symmetry (Figure 1C) (Yu et al., 2008).
The prM protein continues to mask the fusion loop of E-DII until
it is released after furin cleavage and a transition to neutral pH
occurs in the extracellular space. The resulting mature and infec-
tious viruses are relatively smooth particles composed of 90 E
protein dimers and 180 copies of the 70 amino acid M protein.
Figure 1. Structure of the DENV E Protein and Its Arrangement on
the Virion
(A) Ribbon diagram of the antiparallel DENV E protein dimer as seen from the
top and side. Individual domains of the E protein are indicated, as is the fusion
loop at the distal end of E-DII. The N-linked carbohydrate modifications on
E are shown as brown spheres
(B–D) Surface shaded representation of the DENV virion at varying stages of
maturation as determined by cryo-EM reconstruction. The significant confor-
mational differences in the organization of E proteins of the virion during
maturation are evident by comparing structure of spiky immature virions at
(B) neutral and (C) acidic pH. In the latter case, prM is represented in cyan
and the icosahedral asymmetry unit is indicated as a gray triangle. In (D), the
structure of the mature DENV virion is shown. The images presented in
(B)–(D) were created using previously described structures of DENV (Kuhn
et al., 2002; Yu et al., 2008; Zhang et al., 2003).
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three distinct environments defined by their proximity to the 2-,
3-, or 5-fold axis of symmetry (Kuhn et al., 2002; Mukhopadhyay
et al., 2003) (Figure 1D).
The Antigenic Structure of Flaviviruses
Epitopes recognized by neutralizing antibodies have been iden-
tified in all three domains of the E protein; however, many of the
most potent mAbs are virus-type specific and bind epitopes
within E-DIII (Figure 2A) (reviewed in Gromowski and Barrett,
2007; Roehrig, 2003; Sukupolvi-Petty et al., 2007 and references
within). One of the well-characterized neutralizing mAbs, the
anti-WNV E16 antibody, binds four discontinuous loops on the
lateral ridge of WNV E-DIII (E-DIII-LR). E16 blocks WNV infection
at picomolar concentrations in vitro (Oliphant et al., 2005; Pier-
son et al., 2007) and can protect animals against lethal challenge
even when administered with a single dose up to 6 days after in-
fection (Morrey et al., 2007). Structural and biochemical studies
Figure 2. Antigenic Complexity of the Flavivirus
E Protein
(A) All three domains of the E protein contain epitopes recog-
nized by neutralizing antibodies. Domains of the WNV E pro-
tein are labeled as in Figure 1. Residues that impact antibody
binding (shown in magenta) were identified using a yeast-dis-
play mapping approach for a large panel of antibodies, identi-
fying structurally distinct epitopes in E-DIII (below), E-DI, and
E-DII. Epitopes are labeled as described previously (Oliphant
et al., 2006).
(B) The structure of WNV DIII is shown displaying the epitope
recognized by the type-specific mAb E16. Residues of E-DIII
determined by X-ray crystallography to interact directly E16
are highlighted in blue.
(C) The structure of DENV E-DIII is shown displaying the epi-
tope recognized by the sub-complex-specific mAb 1A1D-2
(highlighted in cyan). Note that the epitope for 1A1D-2 is cen-
tered on the A strand and does not make contact with the res-
idues in the FG loop that play a role in type-specific reactivity.
(D) Comparison of the epitope recognized by 1A1D-2 and the
DENV2 type-specific mAb 3H5.
(E) E proteins exist on the mature flavivirus associated with
three distinct symmetry environments. Epitopes recognized
by mAbs may not be equally accessible in all three of these
environments. The WNV-specific mAb E16 binds an epitope
(shown in green) that is accessible in only two of these environ-
ments. As shown in dark green, the E-DIII-LR epitope recog-
nized by E16 is partially obscured on E proteins proximal to
the five-fold axis of symmetry, which limits binding to 120 of
180 possible E proteins on the mature virus. The 1A1D-2 epi-
tope (shown in pink) on E-DIII is partially blocked on E proteins
of mature virus particles regardless of their position on the vi-
rions (shown in red).
identified four amino acids (306, 307, 330, and 332)
on the amino-terminal and BC loops as the core
residues of the interface of E-DIII and E16; these
residues are not conserved among flaviviruses,
which explains the type specificity of this mAb
(Figure 2B) (Nybakken et al., 2005). Molecular
docking and cryoelectron microscopy (cryo-EM)
studies reveal that E16 cannot bind all 180 E pro-
teins on the virion (Kaufmann et al., 2006). Epitopes
on the tightly clustered E proteins along the five-
fold axis of symmetry remain unoccupied due to
steric conflicts. These studies indicate that, at max-
imum, 120 E-DIII-LR epitopes on the mature virion can
simultaneously bind E16. Similarly, some strongly neutralizing
type-specific mAbs that neutralize DENV serotype 2 (DENV2)
(e.g., mAb 3H5) also map to the E-DIII-LR; however, the epitope
recognized by thesemAbs is located on both the A strand (amino
acid 304) and the FG loop (residues 383 and 384) (Figure 2D) (Su-
kupolvi-Petty et al., 2007). Not all antibodies that bind E-DIII ex-
hibit type-specific neutralizing activity. The subcomplex-specific
mAb 1A1D-2 recognizes an epitope centered on the A strand of
the lateral surface of E-DIII and can neutralize infection by DENV
serotypes 1–3, but not DENV4 (Lok et al., 2008; Roehrig et al.,
1998; Sukupolvi-Petty et al., 2007). The molecular basis for the
specificity of this mAb has been investigated; only one of three
residues at the center of the 1A1D-2 epitope is conserved among
all four DENV serotypes (Figure 2C). A similar A-strand epitope is
also recognized by the broadly neutralizing crossreactive DENV
mAb 4E11 (Thullier et al., 2001). Finally, E-DIII epitopes recog-
nizedbyWNV-andDENV-specificmAbswithmodestneutralizing
Cell Host & Microbe 4, September 11, 2008 ª2008 Elsevier Inc. 231
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that are less accessible onmature virions (Gromowski et al., 2008;
Oliphant et al., 2005; Pierson et al., 2007; Roehrig et al., 1998; Su-
kupolvi-Petty et al., 2007). Altogether, structural and biochemical
approaches identify E-DIII as a complex immunogen that elicits
antibodies with varying specificity and functional potency.
Analysis of the B cell repertoire of flavivirus-immune humans
suggest that many antibodies produced in vivo recognize the
E-DII-FL (Throsby et al., 2006). Fusion loop-specific mAbs
exhibit modest neutralization potency in vitro, protect animal
models from WNV infection only at relatively high concentration,
and are often crossreactive (Crill and Chang, 2004; Goncalvez
et al., 2004; Nelson et al., 2008; Oliphant et al., 2006; Stiasny
et al., 2006). The structural basis for the recognition of the
E-DII-FL is not yet clear and may differ among mAbs. Structural
models of themature flavivirus virion do not provide a clear ratio-
nale to explain mAb recognition of intact virus particles because
the fusion loop of each E protein is partially buried at the E-DI and
E-DIII interface of the opposing E protein in the antiparallel dimer
(Kuhn et al., 2002) (Figure 1A). Studies with TBEV demonstrate
that treatment with mild nonionic detergent significantly in-
creases E-DII-FL mAb binding to intact virions, suggesting
accessibility of the E-DII-FL epitope is limited on mature viruses
(Stiasny et al., 2006). However, the molecular details of mAb
binding to this epitope may not be explained by static models
of mature virion structure as described in detail below. Further-
more, the E-DII-FL epitope may be complex, composed of
residues in other loops on the same E protein or residues on
adjacent E proteins within the dimer (Crill and Chang, 2004).
A Moving Target.
Molecular docking of the crystallographic coordinates that de-
fine the E protein-antibody interaction onto a pseudoatomic
model of the mature flavivirus has not always provided a clear
structural basis for antibody recognition and neutralization. In-
deed, some antibodies recognize ‘‘cryptic’’ determinants in the
mature virion, such as the E-DII-FL, yet still exhibit some neutral-
izing activity; this suggests additional complexity not captured
by static models of virion structure (Nelson et al., 2008; Stiasny
et al., 2006). The cryo-EM approaches used to develop the exist-
ing models of virion structure identify the most abundant physi-
cal state of the virus particle and may fail to detect low abun-
dance conformations that exist in a dynamic equilibrium.
Recent cryo-EM experiments suggest that some antibodies
may neutralize flaviviruses by recognizing different states of
the E proteins on the virion. Molecular docking studies indicated
that a significant portion of the 1A1D-2 Fab binding surface
(18%) is buried on E proteins present along all three symmetry
axes of mature DENV virions (Figure 2E), consistent with poor
binding of Fab molecules to the virion at 4C (Lok et al., 2008).
Incubation at physiologic temperatures resulted in Fab binding
and significant changes in the arrangement of the E proteins
on the surface of DENV; this allowed docking of 1A1D-2 Fab
fragments to two of three E proteins in the asymmetric unit
(Lok et al., 2008). The temperature dependence of binding sug-
gests the 1A1D-2mAb stabilized a state present in the ensemble
of possible conformations of the virion at 37C but not 4C. How
many different states exist in the ensemble of structures
sampled by flavivirus virions, and the dynamics that regulate
their relative abundance, is not presently known.232 Cell Host & Microbe 4, September 11, 2008 ª2008 Elsevier IncEngagement of antibodies that recognize low abundance, or
transient, conformations of the E protein may alter the dynamics
that govern the ensemble of conformations sampled by the vi-
rion. This in turn may modulate the efficiency of subsequent
antibody-virion interactions. For 1A1D-2, the binding of Fab
fragments to individual virions appeared to be an ‘‘all or none’’
phenomenon; that virions were either completely decorated by
Fab or intact and unbound, suggested that the binding of a few
Fab fragments might increase the accessibility of the epitope
on surrounding E proteins in a cooperative fashion (Lok et al.,
2008). In the context of a polyclonal response, changes in the
accessibility of one epitope arising from the stabilization of E pro-
teins in alternative conformations by antibodies specific for a dis-
tinct epitope adds to the complexity of understanding the hu-
moral response in mechanistic and quantitative terms.
A Heterogeneous Target.
Cleavage of the prM protein by furin is a required step in the
flavivirus life cycle (Mukhopadhyay et al., 2005). However, this
maturation process can be inefficient, resulting in the release
of virions that incorporate uncleaved prM protein yet remain in-
fectious (Davis et al., 2006; Guirakhoo et al., 1992). Little is
known about the extent of prM cleavage required for infectivity
nor the arrangement of E protein on ‘‘partially mature’’ virions
that incorporate prM protein. The release of heterogeneous pop-
ulations of virions in vivo that differ with respect to the extent of
prM cleavage may be an additional layer of complexity that
shapes the repertoire of epitopes available for antibody binding
and neutralization. Indeed, antibodies interact differently with the
E protein trimers on immature particles compared to antiparallel
dimers on fullymature virions (Guirakhoo et al., 1992; Heinz et al.,
1994). As such, virion maturation impacts the sensitivity of flavi-
viruses to neutralization by some, but not all, antibodies (Nelson
et al., 2008). Antibodies that recognize epitopes predicted to be
poorly or partially exposed on mature virions were significantly
less potent when assayed using a relatively homogeneous pop-
ulations of mature virions, as compared to the heterogeneous
population of virus particles typically released from cells. This re-
duced sensitivity of mature virions to neutralization may be ex-
plained by the inability of some classes of antibodies to engage
the virion with a stoichiometry sufficient for neutralization (see
below) (Nelson et al., 2008). The structural basis for this
phenomenon is not yet clear and may differ for antibodies that
recognize distinct classes of epitopes. Some antibodies may
neutralize partially mature virions more efficiently because they
recognize epitopes that are exposed on a given oligomeric
form of E protein only when prM remains bound. Alternatively,
the presence of prM-E heterotrimers on infectious ‘‘partially
mature’’ virions may alter the dynamics of the ensemble of con-
formations displayed by an individual virion. That the polyclonal
response of 50% of human recipients of two different candi-
date WNV vaccines had substantially less neutralizing activity
against mature WNV virions as compared to partially mature
virions highlights the importance of understanding the composi-
tion of virus populations produced by infected humans and
mosquitoes in vivo (Nelson et al., 2008).
Stoichiometric Models of Neutralization
The number of antibodies required to bind a virion and neutralize
infectivity has been studied extensively. Generally, two models
are favored. ‘‘Single-hit’’ models describe neutralization after.
Cell Host & Microbe
Reviewengagement of the virion with a single antibody (Dulbecco et al.,
1956). Historically, this model is based on the observation that
the neutralization of some viruses appeared to be a first-order
reaction, indicating that multiple antibodies are not required to
inactivate infectivity (which would be suggested by a lag during
kinetic studies). Mechanistically, these models propose that
engagement of the virion at ‘‘critical sites’’ is sufficient to cause
irreversible conformational changes in the virion that render it
noninfectious. In contrast, a ‘‘multiple-hit’’ model of neutraliza-
tion postulates that virus inactivation occurs as a function of
the number of antibodies bound to the virion (Burnet et al.,
1937; Della-Porta and Westaway, 1978). In this case, neutraliza-
tion is reversible and occurs when an individual virion is engaged
with a stoichiometry that exceeds a particular threshold. The
threshold number of antibodies required for neutralization of dif-
ferent virus classes has been investigated and varies signifi-
cantly. While the factors that determine the stoichiometric
threshold for a given virus are not clear, Burton and colleagues
propose that the requirements for neutralization is a reflection
of the number of antibodies required to ‘‘coat’’ the surface
area of the virus particle (Burton et al., 2001). While the stoichio-
metric requirements for neutralization remains somewhat
controversial and may differ between viral systems or among
structurally distinct epitopes, understanding how antibodies
block infection remains an important goal.
The existence of high-resolution structural data and the avail-
ability of large numbers of well-characterizedmAbs identifies fla-
viviruses as a promising system to investigate models for, and
mechanisms of, antibody-mediated neutralization. Several lines
of evidence suggest that flavivirus neutralization by antibodies is
a multiple-hit phenomenon including (1) the relationships be-
tween the affinity of mAbs for the virion and their neutralization
activity in vitro, (2) the demonstration that not all antibodies
can bind the virion with a stoichiometry sufficient for neutraliza-
tion, (3) the ability of complement to augment neutralization, and
(4) the ability of antibodies to enhance flavivirus infection of Fc-g-
receptor bearing cells (Della-Porta and Westaway, 1978; Gro-
mowski and Barrett, 2007; Gromowski et al., 2008; Mehlhop
et al., 2005; Nelson et al., 2008; Pierson et al., 2007). Using the
WNV E-DIII-LR-specific mAb E16, we have investigated the
number of antibodies bound to the virion when it is neutralized
(Pierson et al., 2007). Analysis of the relationship between the
strength of binding and neutralization potential of several DIII-
LR-specific antibodies suggest that neutralization requires en-
gagement of only a modest fraction of the accessible epitopes
on the virion. In agreement, complementary genetic approaches
indicate that neutralization occurs when25%of the 120 acces-
sible E-DIII-LR epitopes on WNV are engaged by antibody, cor-
responding to roughly 30 mAbs (Pierson et al., 2007) (Figure 3).
Of interest, this estimate agrees with the predictions of
the ‘‘coating theory’’ (Burton et al., 2001). Thus, in quantitative
terms, the potent inhibitory activity of E16 is explained by its
high affinity and the relatively small fraction of E-DIII-LR epitopes
on the virion that must be bound by antibody in order to neutral-
ize virus infectivity.
However, not all high-affinity antibodies neutralize flavivirus in-
fection at low concentrations or by binding a small fraction of the
epitopes that are accessible on the virion. In fact, many mAbs
neutralize infection at concentrations that saturate all the acces-Csible epitopes on the virion (Nelson et al., 2008; Pierson et al.,
2007). Because epitopes are not displayed in an identical fashion
on E proteins associated with the three distinct symmetry envi-
ronments of pseudoicosahedral mature flaviviruses (Figure 2E),
the total number of accessible binding sites on the mature flavi-
virus may differ between structurally distinct epitopes. Thus, dif-
ferences in the fraction of epitopes a particular antibody must
bind in order to exceed stoichiometric requirements for neutral-
ization (defined as epitope occupancy) reflect complexities that
arise from the arrangement of E proteins on the mature virion.
Many antibodies with high-occupancy requirements for neutral-
ization recognize epitopes that are predicted to be poorly acces-
sible on the mature virions. Presumably, when few epitopes are
available on the average virion, there is a requirement for
Figure 3. A Model of the Stoichiometric Requirements for Flavivirus
Neutralization
Neutralization of flavivirus infection is a multiple-hit phenomenon that requires
engagement of the virion by antibody with a stoichiometry that exceeds
a threshold (modeled as 30 mAbs based on studies with WNV E-DIII-LR-spe-
cific mAbs; red dashed line) (Pierson et al., 2007). Whether an individual anti-
body can dock on the virion with a stoichiometry sufficient to exceed this
threshold depends on its affinity for viral antigens and the total number of ac-
cessible epitopes on the average virion (shown schematically on the x axis).
Epitopes that are differentially accessible on virions as a function of the extent
of virion maturation or the structural dynamics of the virus particle add to the
complexity of the model (shown schematically for maturation-dependent epi-
topes and those that bind selective conformations, respectively). Neutraliza-
tion via highly accessible determinants can be achieved by engagement to
a relatively low occupancy, whereas antibodies that bind cryptic determinants
must bind a larger fraction of them. Not all epitopes appear to exist on the
average virion at levels that exceed this threshold. Engagement of the virion
with a stoichiometry below this threshold may support antibody-dependent
enhancement of infection. Virion images were created using Chimera (http://
www.cgl.ucsf.edu/chimera) or obtained from the VIPERdb Virus Particle
Explorer (http://viperdb.scripps.edu) (Shepherd et al., 2006).ell Host & Microbe 4, September 11, 2008 ª2008 Elsevier Inc. 233
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chiometric threshold required for neutralization. Indeed, not all
antibodies have the ability to neutralize all virions in a heteroge-
neous population (composed of immature, mature, and partially
mature virions in unknown proportions) (Oliphant et al., 2006).
This ‘‘resistant’’ fraction reflects the existence of individual
virions that do not display a sufficient number of epitopes to
exceed the threshold even when fully occupied by a given anti-
body (Nelson et al., 2008; Pierson et al., 2007). Thus, coupled
with antibody affinity for the virion, epitope accessibility is a crit-
ical parameter that governs the occupancy requirements for
neutralization.
Additional studies are required to understand the details that
define the stoichiometric requirements of flavivirus neutraliza-
tion. Our estimates of the stoichiometric threshold of neutraliza-
tion arise from studies with WNV DIII-LR-specific mAbs. Ex-
panding this analysis to other structural epitopes will be of
significant value and provide an interesting test of the ‘‘coating
theory.’’ However, this is technically quite challenging because,
for many of these other epitopes, the total number of accessible
sites on the average virion is either variable (in the case of
epitopes sensitive to the prM content of virions), or cannot be
determined using existing structural approaches (e.g., epitopes
exposed only on conformations of the virion that are underrepre-
sented in the dynamic ensemble of possible conformations of
the virion) (Figure 3). It is also unclear if the stoichiometric
requirements for neutralization differ between antibodies that
neutralize infection via different mechanisms (see below). Finally,
whether the stoichiometric requirements for neutralization by
mAbs that capture potentially transient conformations of the
virion (e.g., 1A1D-2) differ from our estimates obtained with
E16 is of significant interest and may provide an opportunity to
explore whether one model for neutralization (‘‘single-hit’’ versus
‘‘multiple-hit’’) is appropriate for all antibodies that recognize
a particular virus.
Implications for Antibody-Mediated Enhancement
of Infection
Insight into the stoichiometric requirements for neutralization
provides a biochemical rationale to understand antibody-medi-
ated enhancement of infection (ADE). ADE describes an opsonic
phenomenon by which antibody or antibody plus complement
increases the efficiency or duration of the interaction between
virus and target cells by virtue of interactions with Fc-g- or com-
plement receptors (Cardosa et al., 1983; Gollins and Porterfield,
1984). Our analyses of more than 100 mAbs raised against WNV
and DENV suggest that all antibodies that bind the virion and
neutralize infection have the potential to promote ADE in vitro,
irrespective of their epitope specificity (Oliphant et al., 2006;
Pierson et al., 2007). Detailed functional studies revealed that
the concentrations of antibody that promote maximal enhance-
ment of infection in vitro were very similar to those that neutralize
half the virions in a given experiment (Pierson et al., 2007). This
reflects the fact that neutralization and ADE are two phenomena
related by the number of antibodies bound to the virion. When
half of the virions are engaged by antibody with a stoichiometry
sufficient to inactivate virus infection, the other half are not and
remain infectious. Thus, at the upper limit, the number of anti-
bodies that can promote ADE is defined by the stoichiometric
threshold of neutralization. The minimum number of antibodies234 Cell Host & Microbe 4, September 11, 2008 ª2008 Elsevier Inc.required for ADE, based on experimental data, appears to be ap-
proximately half the number required for neutralization (Pierson
et al., 2007).
Despite intense interest, the characteristics of antibodies that
are likely to enhance infection in vivo have not been deter-
mined. The threshold requirement for neutralization central to
the ‘‘multiple-hit’’ model of neutralization suggests that individ-
ual virions can be bound by antibody with a stoichiometry that
is not sufficient for neutralization. This provides an important
framework upon which to consider the enhancing potential of
antibodies that recognize different classes of epitopes. The
ability of potent neutralizing antibodies (like the E-DIII-LR-spe-
cific mAb E16) to completely block infection at high concentra-
tions of antibody limits their potential for ADE. However, anti-
bodies that recognize poorly accessible epitopes (such as the
E-DII-FL) are often incapable of neutralizing all members of
a heterogeneous population of virions, even under saturating
conditions of antibody. Under these conditions, the fraction of
virions resistant to neutralization may be bound by antibody
with a stoichiometry that promotes ADE. Thus, accessibility of
the epitope is a critical factor for assessing the potential for
a class of antibody to promote ADE (Nelson et al., 2008). Be-
yond stoichiometric considerations, other factors may modu-
late the potential for antibodies to enhance infection including
the glycosylation state of the mAb, its isotype, and the pres-
ence of serum factors such as complement (Mehlhop et al.,
2007). Furthermore, ADE by anti-flavivirus antibodies that pro-
mote more efficient infection through non-Fc receptor-depen-
dent pathways, possibly by enhancing attachment or entry
through distinct mechanisms, may be uniquely regulated
(Huang et al., 2006).
Mechanisms of Neutralization
Many steps in the flavivirus virus entry pathway may be blocked
by antibody including (1) virion attachment to the cell, (2) interac-
tion of virions with host factors required for internalization or
fusion, and (3) E protein-mediated conformational changes that
drive membrane fusion. At present, an incomplete picture of
how flaviviruses interact with permissive cells limits our under-
standing of mechanisms of neutralization. Many of the neutraliz-
ing antibodies characterized using other viral systems inhibit in-
fection by interfering with required interactions between the viral
glycoproteins and cellular receptors. While several molecules
that promote more efficient flavivirus attachment (e.g., DC-
SIGN, DC-SIGNR, heparin sulfate) have been characterized,
cellular receptors required for flavivirus entry have not been iden-
tified (Anderson, 2003). While the relevant interactions are
unclear, inhibition of flavivirus attachment by some mAbs and
flavivirus-immune sera contributes to virus neutralization (Crill
and Roehrig, 2001; He et al., 1995; Nybakken et al., 2005). Addi-
tionally, antibodies that inhibit viral fusion have also been charac-
terized (Gollins and Porterfield, 1986; Roehrig et al., 1998;
Stiasny et al., 2007). Stiasny and colleagues reported that
some but not all antibodies had the capacity to block fusion of
TBEV with synthetic liposome (Stiasny et al., 2007). A similar
result has been obtained using the WNV-specific mAb E16
(B.S. Thompson, B.J.S. Moesker, J.M. Smit, J. Wilschut,
M.S.D., and D.H.F., unpublished data). In the latter case, molec-
ular docking studies of E16 Fab fragments on mature virions
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and organization changes in E proteins that drive fusion at low
pH (Kaufmann et al., 2006; Nybakken et al., 2005).
The mechanisms by which a given antibody neutralizes infec-
tion may depend upon circumstance, as single antibodies may
blockmore than one step in the viral entry pathway. For example,
the mAb E16 is capable of blocking both viral fusion and attach-
ment of WNV to cells (Nybakken et al., 2005). Whether an ability
to neutralize infection via multiple mechanisms is a common fea-
ture of the most potent antibodies remains unclear. Thus, while
several steps in the flavivirus entry pathway that may be
inhibited by antibody have been cataloged, future studies are re-
quired to identify factors that regulate these distinct neutraliza-
tion mechanisms.
The Role of Fc-Dependent Effector Functions of
Antibodies in Protection against Flavivirus Infection
Beyond direct virus neutralization, antibody binding to virions or
virus-infected cells can trigger protective Fc-dependent antiviral
activities through complement activation or Fc-g-receptor-me-
diated immune complex clearance mechanisms. Fc-g receptors
are expressed on a wide variety of immune cells and belong to
a multigene immunoglobulin-like superfamily that can activate
or inhibit immune responses depending on their cytoplasmic do-
main or association with specific signaling molecules (Nimmer-
jahn and Ravetch, 2008). Recent studies indicate that interaction
of the Fc region of antibodies with activating Fc-g receptors can
augment antibody protection against flavivirus infection in vivo.
Mice lacking all activating Fc-g receptors required significantly
higher doses of a neutralizing E protein-specific mAb to maintain
equivalent levels of protection against lethal WNV infection (Oli-
phant et al., 2006), and Fab2 fragments of a neutralizing mAb
were less protective in mice (Gould et al., 2005).
Ab-Mediated Complement Activation and Protection
The complement system is a family of 30 serum and cell-sur-
face proteins that recognize and clear pathogens and activate in-
flammatory responses (Carroll, 2004). The complement cascade
protects generally against viral infection through lysis of virions
or infected cells, release of proinflammatory peptides, opsoniza-
tion and neutralization of viruses, targeting to complement
receptor-expressing cells, and facilitating antigen presentation
and immune cell priming. Opsonization of enveloped RNA
viruses with classical pathway complement components (C1q,
C4b, and C3b) in an antibody-dependent manner can inhibit
receptor attachment or viral fusion and promote the formation
of C5b-C9 membrane attack components that induce virolysis.
Indeed, the absence of classical pathway complement compo-
nents leads to more severe primary WNV infection (Mehlhop
et al., 2005). More recent studies demonstrate that for the spe-
cific IgG subclasses that bind C1q avidly (mouse IgG2a and
2b; human IgG1 and 3), complement augments antibody-medi-
ated neutralization of WNV and DENV in vitro and increases the
functional potency of a strongly neutralizing anti-WNV antibody
in mice in an IgG-subclass-specific manner (E. Mehlhop,
S. Nelson, C.A. Jost, S. Johnson, D.H.F., M.S.D., and T.C.P., un-
published data). In agreement, a mouse IgG2a isotype-switch
variant of an E protein-specific mAb against YFV protected
mice more efficiently from lethal infection than the parental
IgG1 (Schlesinger and Chapman, 1995).Implications for the Development of Novel Flavivirus
Vaccines
The characteristics of a protective humoral immune response eli-
cited by natural infection or vaccination have not been defined in
molecular terms. Current in vitro markers and assays are not re-
liable surrogates of protection in vivo. The root of this problem
may be that existing approaches cannot measure the contribu-
tion of relevant specificities or functional properties of a humoral
response against the backdrop of a complex and extensively
crossreactive polyclonal antibody response. For example, neu-
tralizing titers induced by the tetravalent vaccines against
DENV as determined using the standard assay (plaque reduction
neutralization test) have not completely correlated with protec-
tion in challenged non-human primates (Blaney et al., 2005).
Efforts to elucidate the structural, functional, and biophysical
correlates of antibody-mediated protection will facilitate the
identification of protective epitopes in vivo, inform the develop-
ment of assays capable of specifically measuring responses to
these determinants, and guide the refinement of vaccination
strategies to focus and augment the humoral response.
Epitope-Specific Diagnostics
The development of DENV vaccines is actively progressing; the
first generation of tetravalent candidate DENV vaccines will soon
be employed in large clinical trials in DENV endemic regions to
evaluate safety and efficacy in humans. However, the tools to
quantitatively describe the features of protective and nonprotec-
tive humoral responses are not yet available. For example, it
remains unclear if four distinct type-specific responses are
required to achieve protection against all four serotypes of
DENV. Furthermore, how a protective repertoire of antibody
changes over time and with repeated exposure to DENV anti-
gens may provide new insights into optimizing vaccine delivery
schedules and informour understanding of the durability of a pro-
tective response. To this end, the development of epitope-spe-
cific measures of anti-flavivirus antibodies will clarify the levels
and functional contribution of different classes of antibody
in vivo. For example, the epitope specificity and functional activ-
ity of the natural antibody response againstWNV inmice, horses,
and humans has been investigated using loss-of-function E pro-
teins, E-DIII, or viral variants that lacked the capacity to bind an-
tibodies specific for the E-DIII-LR epitope (Oliphant et al., 2007;
Sanchez et al., 2007). While E16-like antibodies can be detected
in convalescent serum, the functional role for E-DIII-LR-specific
antibodies during the response to WNV infection appears mod-
est despite their potent neutralizing activity. Similar results were
observed during the analysis of the humoral response of recipi-
ents of two different candidate WNV vaccines (Nelson et al.,
2008). In contrast, a significant fraction of E protein-specific B
cells appear to produce antibodies specific for the E-DII-FL
(Throsby et al., 2006), and antibodies against this determinant
are readily detected in serum. Using a similar approach, muta-
tions in the fusion loop have improved the accuracy of serum di-
agnostic assays for DENV, JEV, and SLEV by eliminating detec-
tion of the highly crossreactive fusion loop antibodies (Chiou
et al., 2008, and references within). As a more detailed under-
standing of the structural basis of antibody recognition and neu-
tralization of flaviviruses emerges, it may be possible to generate
high-throughput epitope-based diagnostic assays with a series
of E protein variants that defines serotype specificity andCell Host & Microbe 4, September 11, 2008 ª2008 Elsevier Inc. 235
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vaccination.
Novel Flavivirus Immunogens
Induction of neutralizing antibodies is critical for the efficacy of
many antiviral vaccines, and the structural and functional charac-
teristics of the most potent anti-flavivirus neutralizing antibodies
are becoming clear. Beyond simply eliciting antibodies that rec-
ognize viral antigens with high affinity, the goal of recombinant
immunogens should be to target accessible determinants on
the mature virion that allow for neutralization at low occupancy
and reduce the potential for ADE. Existing vaccination strategies
may produce strong anti-flavivirus antibody responses against
viral structural proteins, as measured by ELISA, that do not cor-
respond to high neutralizing titers in vitro or in vivo protection
(Despres et al., 2005; Throsby et al., 2006). This disparity may
be due to the repertoire of antibodies elicited by a particular im-
munogen. Our improved understanding of the structural and
mechanistic correlates of antibody protection may inform novel
strategies for modifying E proteins to preserve specific neutraliz-
ing epitopes and subtract or mask immunodominant poorly neu-
tralizing epitopes that may have the potential to support ADE
in vivo. The feasibility of this approach has been established by
studies that direct the immune response away from non-neutral-
izing antibodies against HIV gp120 (Pantophlet and Burton,
2003). However, the design of a tailored flavivirus immunogen
will likely require an iterative process. One primary decision will
be whether to use the whole ectodomain of the envelope protein
or E-DIII alone as the immunogen. While E-DIII contains the
strongly neutralizing lateral ridge epitope, it also displays a highly
crossreactive immunodominant non-neutralizing epitope in the
AB loop (Sukupolvi-Petty et al., 2007). Furthermore, strongly neu-
tralizing and highly protective antibodies in DI have recently been
described against DENV and JEV (Goncalvez et al., 2008; Lai
et al., 2007); it is not clear whether responses to these epitopes
are functionally important in vivo. Additionally, domains I and II
may contain important class II MHC-dependent epitopes that
are necessary for T cell-directed affinity maturation. Indeed, re-
cent studies indicate that neutralizing antibody responses
against a given epitope of vaccinia virus is augmented by coim-
munization with a linked immunodominant class II MHC-re-
stricted viral peptide (Sette et al., 2008). While the development
of novel immunogens capable of eliciting (or boosting) type-spe-
cific or protective responses are at early stages, these efforts are
informed by continued advances in our basic understanding of
themechanisms that govern antibody potency in vitro and in vivo.
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